Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 18;41(11):2647–2657. doi: 10.1038/npp.2016.60

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 American College of Neuropsychopharmacology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Results of subjective rating scales from the alcohol infusion challenge: the plots show the least square means for each treatment compared with placebo across both genotypes at each breath alcohol concentration; error bars are SE of the LS means. GSK1521498 significantly attenuated the hedonic response to alcohol as measured by the Alcohol Rating Scale (ARS) and the Subjective High Assessment Scale (SHAS), ie, alcohol was overall less pleasurable (see top panel). NTX decreased the experienced stimulating effects of alcohol (BAES stimulant items) such as elation and excitement as well as feelings of vigor and energy (POMS-B vigor). All significant effects are main effects of treatment across all breath alcohol concentrations. *P<0.05 versus placebo, ^#p<0.05 NTX vs GSK1521498. ***p<0.001.